ECSP15029636A - Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa - Google Patents

Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa

Info

Publication number
ECSP15029636A
ECSP15029636A ECIEPI201529636A ECPI201529636A ECSP15029636A EC SP15029636 A ECSP15029636 A EC SP15029636A EC IEPI201529636 A ECIEPI201529636 A EC IEPI201529636A EC PI201529636 A ECPI201529636 A EC PI201529636A EC SP15029636 A ECSP15029636 A EC SP15029636A
Authority
EC
Ecuador
Prior art keywords
beta
antibacterial agents
lactamase inhibitors
bicyclic compounds
new bicyclic
Prior art date
Application number
ECIEPI201529636A
Other languages
English (en)
Inventor
Jehangir Khan
Samarendra N Maiti
Rong Ling
Dai Nguyen
Original Assignee
Fedora Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fedora Pharmaceuticals Inc filed Critical Fedora Pharmaceuticals Inc
Publication of ECSP15029636A publication Critical patent/ECSP15029636A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Fórmula (I), en donde: M es hidrógeno o un catión formador de sales farmacéuticamente aceptable; Y es OR1 o NR2R3, y R1, R2, R3 y M son como se definen en el presente documento. Además, los métodos de tratamiento de la infección bacteriana, composiciones farmacéuticas, complejos moleculares y procesos para la preparación de compuestos.
ECIEPI201529636A 2012-12-11 2015-07-10 Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa ECSP15029636A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/002675 WO2014091268A1 (en) 2012-12-11 2012-12-11 NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP15029636A true ECSP15029636A (es) 2016-01-29

Family

ID=50933808

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201529636A ECSP15029636A (es) 2012-12-11 2015-07-10 Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa

Country Status (18)

Country Link
EP (1) EP2931723B1 (es)
JP (1) JP2016503000A (es)
KR (1) KR20150093809A (es)
CN (1) CN105873930B (es)
AU (1) AU2012396338B2 (es)
BR (1) BR112015013450A8 (es)
CA (1) CA2893804C (es)
CR (1) CR20150359A (es)
EA (1) EA028633B1 (es)
EC (1) ECSP15029636A (es)
ES (1) ES2817785T3 (es)
IL (1) IL239116B (es)
MA (1) MA38227B1 (es)
MX (1) MX2015007406A (es)
PH (1) PH12015501303A1 (es)
SG (1) SG11201504540TA (es)
UA (1) UA111925C2 (es)
WO (1) WO2014091268A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091222A1 (es) * 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
IN2014MU00194A (es) * 2014-01-21 2015-08-28 Wockhardt Ltd
CN105801579A (zh) * 2014-12-31 2016-07-27 卢来春 一种β-内酰胺酶抑制剂
WO2016120752A1 (en) * 2015-01-28 2016-08-04 Wockhardt Limited A process for preparation of (2s, 5r)-n-(2-amino ethoxy)-6-(sulfooxy)-7-oxo-1,6- diazabicyclo [3.2.1] octane-2-carboxamide
WO2017002087A1 (en) * 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
JP2018515481A (ja) 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー,リミティド β−ラクタマーゼ阻害剤とその利用
CA3000087A1 (en) 2015-10-02 2017-04-06 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017081615A1 (en) * 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
WO2017098425A1 (en) * 2015-12-11 2017-06-15 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
WO2017206948A1 (zh) * 2016-06-03 2017-12-07 南京明德新药研发股份有限公司 新型二氮杂二环β-内酰胺酶抑制剂
KR102392350B1 (ko) * 2016-06-03 2022-04-29 치루 파머수티컬 컴퍼니 리미티드 신규 β-락타마제 억제제
WO2017216764A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-(alkanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide derivatives and their use as antibacterial agents
WO2017216763A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-phenylalkoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives and their use as antibacterial agents
JP7012924B2 (ja) * 2017-03-02 2022-02-15 ウォックハート リミテッド 抗菌化合物としての複素環誘導体
CN106831772B (zh) * 2017-03-04 2019-12-17 丽珠医药集团股份有限公司 一种阿维巴坦中间体的合成方法
WO2018203194A1 (en) * 2017-05-02 2018-11-08 Wockhardt Limited Diazabicyclooctane derivatives comprising a quaternery ammonium group for use as antibacterial agents
WO2018203197A1 (en) * 2017-05-02 2018-11-08 Wockhardt Limited Diazabicyclooctane derivatives comprising an oxyimino group for use as antibacterial agents
CN107383034A (zh) * 2017-06-29 2017-11-24 上海药明康德新药开发有限公司 外消旋‑5‑(叔丁氧羰基)‑八氢呋喃并[3,2‑c]吡啶‑3a‑羧酸的合成方法
CN110446708B (zh) 2017-07-21 2022-12-02 安塔比奥公司 化学化合物
WO2019064071A1 (en) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN111417633B (zh) * 2017-12-01 2022-05-06 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的晶型及其制备方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
KR102790878B1 (ko) * 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
EP3608318A1 (en) * 2018-08-09 2020-02-12 Antabio SAS Diaazabicyclooctanone derivatives as antibacterials
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN113292499B (zh) * 2020-02-24 2024-05-28 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的新制备方法及其中间体
CN117384169B (zh) * 2022-07-05 2025-10-17 福安药业集团重庆三禾兴医药科技有限公司 一类噻唑胺-二氮杂双环辛酮缀合衍生物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337197A (en) 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2672327A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
US8829191B2 (en) * 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
KR101512738B1 (ko) * 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections

Also Published As

Publication number Publication date
NZ709355A (en) 2017-09-29
EA201500544A1 (ru) 2015-12-30
AU2012396338A1 (en) 2015-07-16
BR112015013450A2 (pt) 2017-07-11
MX2015007406A (es) 2015-12-03
UA111925C2 (uk) 2016-06-24
CR20150359A (es) 2015-08-20
EP2931723B1 (en) 2020-08-26
AU2012396338B2 (en) 2017-09-28
MA38227A1 (fr) 2016-12-30
IL239116B (en) 2019-05-30
SG11201504540TA (en) 2015-07-30
EA028633B1 (ru) 2017-12-29
CN105873930B (zh) 2019-02-19
EP2931723A1 (en) 2015-10-21
KR20150093809A (ko) 2015-08-18
IL239116A0 (en) 2015-07-30
PH12015501303A1 (en) 2015-08-24
CA2893804A1 (en) 2014-06-19
ES2817785T3 (es) 2021-04-08
EP2931723A4 (en) 2016-06-01
WO2014091268A1 (en) 2014-06-19
CA2893804C (en) 2021-05-18
MA38227B1 (fr) 2017-10-31
BR112015013450A8 (pt) 2019-10-08
JP2016503000A (ja) 2016-02-01
CN105873930A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
MX2015007406A (es) NUEVOS COMPUESTOS BICICLICOS Y SU USO COMO AGENTES ANTIBACTERIANOS E INHIBIDORES DE ß-LACTAMASA.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
UY34723A (es) ?compuestos de 7-oxo-1,6-diazabiciclo[3.2.1]oct-3-en-6-ilo sustituidos para usarse como inhibidores de la betalactamasa?.
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
PE20140864A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
MX2018005382A (es) Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
CO6660502A2 (es) Compuestos macrocíclicos como inhibidores de quinasa trk
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
PE20150966A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
CR20170021A (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
ECSP11011258A (es) Pirimidinas fusionadas
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur